Unibest
← Back to patent-cliff list

CAS 2730017-97-5

(5S,6S)-5-(Benzyloxy)-6-[(4S,5S)-2,2-dimethyl-5-(6,6,8-trimethyl-1,4-dithiaspiro[4.5]dec-7-en-7-yl)-1,3-dioxolan-4-yl]-2,6-dimethylcyclohex-1-ene-1-carbaldehyde

Codes: (X)101438-71-a

Application context (from source-drug indications)

Breast cancerPaclitaxel/Encequidar mesylateAdenocarcinomaPaclitaxel/Encequidar mesylateAngiosarcomaPaclitaxel/Encequidar mesylateSolid tumourPaclitaxel/Encequidar mesylatePancreatic cancerPaclitaxelNon-small cell lung cancerPaclitaxelHodgkin's diseasePaclitaxelSeminomaPaclitaxelOvarian cancerPaclitaxelBreast cancerPaclitaxel

Source drugs (routes using this intermediate)

DrugTierExpiry
Paclitaxel/Encequidar mesylateTier C — Watch / trade-
PaclitaxelTier B — Position early-

Position in synthesis routes (up/downstream chain)

Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.

Paclitaxel/Encequidar mesylateOptimised routesteps: 11total yield: /
PaclitaxelOptimised routesteps: 11total yield: /

Intermediates available on this site

No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.

This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.